Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study.

ABSTRACT:

Background

The long-term safety and efficacy of fremanezumab were evaluated in a 52-week extension study (NCT02638103). Patient satisfaction with fremanezumab, dosing preferences, and patient-reported outcomes were assessed in a subpopulation who completed the extension study and consented to a follow-up questionnaire.

Methods

In the extension study (N = 1842), adults with migraine were randomized to quarterly or monthly fremanezumab. After completing active treatment, patients answered a survey evaluating patient satisfaction, treatment and dosing preferences, and changes in patient-reported outcomes.

Results

Of the 557 patients who could have been contacted upon completing the extension study, 302 consented and 253 completed the survey. The mean (standard deviation)

SUBMITTER: Buse DC 

PROVIDER: S-EPMC7487845 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature